Last updated: 2026-09-05 17:06:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Spruce Biosciences, Inc. (SPRB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $57.77, with a market capitalization of $171.49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.26 to $240.00. This page covers its latest market performance, valuation, price trends and company information.
$171.49M | |
$57.37 | |
$2,670.00 | |
$4.28 | |
$57.71 | |
102.13K | |
-- | |
-- | |
$240.00 | |
$7.26 | |
-- | |
-- |
Spruce Biosciences, Inc. (SPRB) last closed at $57.71 as of 2026-09-05 00:00:00, unchanged from the previous close of $57.71.
During the latest regular trading session, SPRB traded between $4.28 and $2,670.00, with a volume of 102.13K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Spruce Biosciences, Inc. (SPRB) moved from $60.54 to $57.77, representing a decline of 4.58% ($2.77).
The stock traded between $56.62 and $58.85 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 101.86 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 21.7%
SPRB is currently trading at $57.77, placing it 21.7% of the way from its 52-week low of $7.26 to its 52-week high of $240.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Spruce Biosciences, Inc. (SPRB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.